Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Managing ART With Opportunistic Infections

Source: Key Decisions in HIV Care
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in the setting of opportunistic infections. Topics include current data and recommendations for patients with pneumocystis pneumonia, Kaposi sarcoma, cytomegalovirus, and cryptococcal meningitis.
Cristina Mussini, MD
William R. Short, MD, MPH, AAHIVS
Released: April 5, 2022

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including:

  • When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infections
  • EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infections
  • Considerations for the administration of ART to patients who are unable to swallow or critically ill and intubated
  • Treatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatment
  • Considerations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirus
  • Discussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ART
  • When to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infection
  • EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specifically
  • Treatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapy

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

Cristina Mussini, MD

Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD, has disclosed that she has received consulting fees from AbbVie, Angelini, Gilead Sciences, Janssen, MSD, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, MSD, and ViiV Healthcare.
William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Related Content

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 30, 2022

Slides from CCO: Discussion of key data and recommendations for managing ART in the setting of opportunistic infections

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: March 21, 2022

Dr Milosz Parczewski, discusses the latest data on LA PrEP, HCV treatment in PWH, and treatments for MDR TB presented at CROI 2022 and their relevance to the CEE, from Clinical Care Options (CCO).

Milosz Parczewski, MD, PhD Released: March 11, 2022

Expert insight on key ART considerations for people with HIV requiring treatment for drug-susceptible tuberculosis (TB), from Clinical Care Options (CCO)

Daria Podlekareva, MD, PhD Released: March 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings